Amid US Cough Syrup Findings, Regulators Feel India Needs To Work On Perceptions But Also Make Improvements
Executive Summary
In wake of the furore caused by OTC cough syrups made by two small Indian companies, former and current US FDA and MHRA officials say quality-related issues are not specific to India. However, while image management needs some work, manufacturers in the country also need to make further improvements to ensure quality.
You may also be interested in...
US Regulatory Risks, Litigation Likely To Slow FY24 Growth For India’s Top Pharma Firms, Says ICRA
The damage at one of Pfizer’s largest injectables facilities could lead to gains for a few Indian companies, analysts feel. However, regulatory risks, litigation pay-outs and other challenges will slow growth for domestic firms and Indian units of multinationals like Abbott and Pfizer in FY24, says rating agency ICRA as Q1 results begin coming in
Quality Street: India Needs A Frances Kelsey, Many Of Her Kind
Scrip delves into some of India’s critical compliance and quality challenges and efforts to address those.
FDA’s McMullen: No Bigger Waste Than Drug Shortages Due To Data Integrity
FDA officials highlight at a recent summit in India recurring issues around drug manufacturing compliance including microbial contamination and data integrity concerns but emphasize that the agency isn’t in a “gotcha” mode for companies.